Cover Image
市場調查報告書

暴食症:開發中產品分析

Binge Eating Disorder - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 283206
出版日期 內容資訊 英文 58 Pages
訂單完成後即時交付
價格
Back to Top
暴食症:開發中產品分析 Binge Eating Disorder - Pipeline Review, H2 2016
出版日期: 2016年10月29日 內容資訊: 英文 58 Pages
簡介

所謂暴食症是因抑制不了的暴飲暴食造成體重增加的嚴重狀態。暴食症的原因至今未明。但家族病史、生物學要素、長期節食及心理性問題會提高風險。主要的症狀有異常地大量進食、一個人頻繁進食、感覺無法控制自己的進食行為,以及心情低落不安等。主要的治療方法有心理治療、投藥療法及行動療法的減重計畫等。

本報告提供全球各國治療暴食症所用的開發中產品之開發情形相關分析,提供您產品開發·上市的最新趨勢,及臨床實驗的各階段產品一覽,主要企業簡介,主要藥物概要,最新的產業趨勢等資訊。

簡介

  • 調查範圍

暴食症概要

治療藥的開發

  • 開發中產品的概要

暴食症:企業開發中的治療藥

暴食症:開發中產品概況

  • 後期階段的產品
  • 臨床階段的產品
  • 初期階段的產品
  • 開發階段不明的產品

暴食症:企業開發中的產品

暴食症的治療藥開發企業

  • Heptares Therapeutics Limited
  • Omeros Corporation
  • Opiant Pharmaceuticals, Inc.
  • Polleo Pharma Limited
  • Sunovion Pharmaceuticals Inc.
  • Teva Pharmaceutical Industries Ltd.

暴食症:治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

暴食症:最近的開發平台趨勢

暴食症:暫停中的計劃

暴食症:開發中止的產品

暴食症:產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC8610IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Binge Eating Disorder - Pipeline Review, H2 2016, provides an overview of the Binge Eating Disorder (Central Nervous System) pipeline landscape.

Binge eating disorder is a serious condition characterized by uncontrollable eating and resulting weight gain. The causes of binge-eating disorder are unknown. But family history, biological factors, long-term dieting and psychological issues increase your risk. Signs and symptoms include eating unusually large amounts of food, frequently eating alone, feeling that eating behavior is out of control and experiencing depression and anxiety. Treatment includes psychotherapy, medications and behavioral weight-loss programs.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Binge Eating Disorder - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Binge Eating Disorder (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Binge Eating Disorder (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Binge Eating Disorder and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Preclinical stages are 1, 2, 1 and 4 respectively for Binge Eating Disorder.

Binge Eating Disorder (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Binge Eating Disorder (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Binge Eating Disorder (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Binge Eating Disorder (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Binge Eating Disorder (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Binge Eating Disorder (Central Nervous System)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Binge Eating Disorder (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Binge Eating Disorder (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Binge Eating Disorder Overview
  • Therapeutics Development
    • Pipeline Products for Binge Eating Disorder - Overview
  • Binge Eating Disorder - Therapeutics under Development by Companies
  • Binge Eating Disorder - Pipeline Products Glance
    • Late Stage Products
    • Clinical Stage Products
    • Early Stage Products
  • Binge Eating Disorder - Products under Development by Companies
  • Binge Eating Disorder - Companies Involved in Therapeutics Development
    • Chronos Therapeutics Limited
    • F. Hoffmann-La Roche Ltd.
    • Heptares Therapeutics Limited
    • Highland Therapeutics, Inc.
    • Omeros Corporation
    • Opiant Pharmaceuticals, Inc.
    • Shire Plc
    • Sunovion Pharmaceuticals Inc.
  • Binge Eating Disorder - Therapeutics Assessment
    • Assessment by Monotherapy Products
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Drug Profiles
    • CTDP-002 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dasotraline hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dextroamphetamine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • lisdexamfetamine dimesylate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • naloxone hydrochloride - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • OMS-527 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RO-5256390 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Small Molecule to Antagonize Orexin 1 for Central Nervous System Disorders - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Binge Eating Disorder - Dormant Projects
  • Binge Eating Disorder - Discontinued Products
  • Binge Eating Disorder - Product Development Milestones
    • Featured News & Press Releases
      • Oct 17, 2016: Shire Announces Update to Vyvanse (lisdexamfetamine dimesylate) U.S. Labeling to Include New Longer-Term Maintenance of Efficacy Data in Adults with Moderate to Severe Binge Eating Disorder
      • Oct 06, 2016: Study Finds New Approach to Block Binge Eating
      • Apr 14, 2016: Shire Submits NDA to FDA for New Formulation of Vyvanse (lisdexamfetamine dimesylate) CII as Chewable Tablets
      • Jan 25, 2016: Sunovion Announces Results from a Study Evaluating the Abuse Potential of Investigational Drug Dasotraline
      • Jul 22, 2015: Vyvanse (lisdexamfetamine dimesylate) Positive Top-Line Results in Maintenance of Efficacy Study in Adults with Moderate to Severe Binge Eating Disorder
      • Jun 13, 2015: PTAB Invalidates Lucerne Biosciences' '813 Patent for the Treatment of Binge Eating Disorder with Lisdexamfetamine Dimesylate
      • May 11, 2015: Shire to Present New Research at American Psychiatric Association Annual Meeting
      • Jan 30, 2015: Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) Becomes First and Only Treatment Approved by the FDA for Adults with Moderate to Severe Binge Eating Disorder
      • Sep 15, 2014: Shire Announces FDA Acceptance for Filing with Priority Review of Supplemental New Drug Application (sNDA) for Vyvanse (lisdexamfetamine dimesylate) Capsules (CII) for Adults with Binge Eating Disorder
      • Nov 05, 2013: Positive Top-line Results Shown for Vyvanse Capsules in Adults with Binge Eating Disorder
      • May 17, 2013: Shire To Present Scientific Data On Vyvanse At 166th APA Annual Meeting 2013
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for Binge Eating Disorder, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Clinical Stage Development, H2 2016
  • Comparative Analysis by Early Stage Development, H2 2016
  • Products under Development by Companies, H2 2016
  • Binge Eating Disorder - Pipeline by Chronos Therapeutics Limited, H2 2016
  • Binge Eating Disorder - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016
  • Binge Eating Disorder - Pipeline by Heptares Therapeutics Limited, H2 2016
  • Binge Eating Disorder - Pipeline by Highland Therapeutics, Inc., H2 2016
  • Binge Eating Disorder - Pipeline by Omeros Corporation, H2 2016
  • Binge Eating Disorder - Pipeline by Opiant Pharmaceuticals, Inc., H2 2016
  • Binge Eating Disorder - Pipeline by Shire Plc, H2 2016
  • Binge Eating Disorder - Pipeline by Sunovion Pharmaceuticals Inc., H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Stage and Target, H2 2016
  • Number of Products by Stage and Mechanism of Action, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Binge Eating Disorder - Dormant Projects, H2 2016
  • Binge Eating Disorder - Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for Binge Eating Disorder, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Assessment by Monotherapy Products, H2 2016
  • Number of Products by Targets, H2 2016
  • Number of Products by Stage and Targets, H2 2016
  • Number of Products by Mechanism of Actions, H2 2016
  • Number of Products by Stage and Mechanism of Actions, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Stage and Molecule Types, H2 2016
Back to Top